Last updated on January 2019

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)


Brief description of study

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Clinical Study Identifier: NCT03443973

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: WN39658 ...

National Hospital Organization Hiroshima-Nishi Medical Center
Hiroshima, Japan
0.91miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.